Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review

Basit Öğe Kaydı
dc.contributor.authorSahin, Ibrahim
dc.contributor.authorBakiner, Okan
dc.contributor.authorDemir, Tevfik
dc.contributor.authorSari, Ramazan
dc.contributor.authorAtmaca, Aysegul
dc.date.accessioned2024-08-04T20:56:12Z
dc.date.available2024-08-04T20:56:12Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe increasing burden of type 2 diabetes (T2D), in relation to alarming rise in the prevalence; challenges in the diagnosis, prevention, and treatment; as well as the substantial impact of disease on longevity and quality of life, is a major concern in healthcare worldwide. Sulfonylureas (SUs) have been a cornerstone of T2D pharmacotherapy for over 60 years as oral antidiabetic drugs (OADs), while the newer generation SUs, such as gliclazide modified release (MR), are known to be associated with low risk of hypoglycemia in addition to the cardiovascular neutrality. This scoping review aimed to specifically address the current position of gliclazide MR among other SUs in the contemporary treatment paradigm for T2D and to provide a practical guidance document to assist clinicians in using gliclazide MR in real-life clinical practice. The main topics addressed in this paper include the role of early and sustained glycemic control and use of SUs in T2D management, the properties of gliclazide MR in relation to its effectiveness and safety, the use of gliclazide therapy in special populations, and the place of SUs as a class and gliclazide MR specifically in the current T2D treatment algorithm.en_US
dc.description.sponsorshipServier Affaires Medicales; Servier Turkeyen_US
dc.description.sponsorshipThis study was supported by Servier Turkey which played a role in organization of the expert panel meeting including the invitation of participants and compensation for the time and transport expenses of the experts. Servier Turkey had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Servier Affaires Medicales funded the Rapid Service Fee.en_US
dc.identifier.doi10.1007/s13300-024-01612-8
dc.identifier.endpage1716en_US
dc.identifier.issn1869-6953
dc.identifier.issn1869-6961
dc.identifier.issue8en_US
dc.identifier.pmid38935188en_US
dc.identifier.scopus2-s2.0-85197930839en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1687en_US
dc.identifier.urihttps://doi.org/10.1007/s13300-024-01612-8
dc.identifier.urihttps://hdl.handle.net/11616/102106
dc.identifier.volume15en_US
dc.identifier.wosWOS:001256959700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofDiabetes Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGliclazideen_US
dc.subjectSulfonylureasen_US
dc.subjectType 2 diabetesen_US
dc.subjectSafetyen_US
dc.subjectEfficacyen_US
dc.subjectGlycemic controlen_US
dc.subjectHypoglycemiaen_US
dc.subjectCardiovascular risken_US
dc.subjectExpert panelen_US
dc.titleCurrent Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Reviewen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu